Poly Medicure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Poly Medicure şirketinin toplam hissedar öz sermayesi ₹25.9B ve toplam borcu ₹1.6B olup, bu da borç-öz sermaye oranını 6.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹30.5B ve ₹4.6B dir. Poly Medicure 'in FAVÖK'ü ₹3.4B faiz karşılama oranı 376 dur. Şirketin ₹12.5B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

6.1%

Borç/özkaynak oranı

₹1.58b

Borç

Faiz karşılama oranı	376x
Nakit	₹12.51b
Eşitlik	₹25.91b
Toplam yükümlülükler	₹4.61b
Toplam varlıklar	₹30.52b

Son finansal sağlık güncellemeleri

Recent updates

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14

Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Jul 07

Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

Jun 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: POLYMED 'nin kısa vadeli varlıkları ( ₹19.2B ) kısa vadeli yükümlülüklerini ( ₹4.2B ) aşıyor.

Uzun Vadeli Yükümlülükler: POLYMED şirketinin kısa vadeli varlıkları ( ₹19.2B ) uzun vadeli yükümlülüklerini ( ₹440.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: POLYMED şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: POLYMED 'nin borç/öz sermaye oranı son 5 yılda 35.6% seviyesinden 6.1% seviyesine düştü.

Borç Kapsamı: POLYMED 'nin borcu işletme nakit akışı ( 160.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: POLYMED 'in borcuna ilişkin faiz ödemeleri EBIT ( 376 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/20 14:42
Gün Sonu Hisse Fiyatı	2025/01/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Poly Medicure Limited 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Nitin Bhasin	Ambit Capital
Karan Khanna	Ambit Capital
Sunita Vaidyanathan	Brics Securities Limited

Poly Medicure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Recent updates

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

New minor risk - Share price stability

Price target increased by 12% to ₹2,475

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 8.3% to ₹2,198

Poly Medicure Limited Appoints Vimal Bhandari as Non-Executive and Independent Director

Poly Medicure Limited Announces Board Cassation

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Dividend of ₹3.00 announced

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure Limited, Annual General Meeting, Sep 26, 2024

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 16%

Poly Medicure Limited has filed a Follow-on Equity Offering in the amount of INR 10 billion.

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Poly Medicure Limited to Report Q1, 2025 Results on Jul 22, 2024

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Price target increased by 12% to ₹1,950

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Full year 2024 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Recommends Dividend for the Financial Year 2023-24

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited to Report Q4, 2024 Results on May 17, 2024

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Price target increased by 9.4% to ₹1,718

Price target increased by 7.5% to ₹1,620

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Poly Medicure Limited to Report Q3, 2024 Results on Jan 31, 2024

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Poly Medicure Limited to Report Q2, 2024 Results on Nov 04, 2023

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Upcoming dividend of ₹3.00 per share at 0.2% yield

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Poly Medicure Limited, Annual General Meeting, Sep 28, 2023

Insufficient new directors

Joint MD & Executive Director recently sold ₹146m worth of stock

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Price target increased by 18% to ₹1,299

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 18%

Poly Medicure Limited to Report Q1, 2024 Results on Aug 07, 2023

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Investor sentiment improves as stock rises 16%

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Full year 2023 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Proposes Dividend for the Financial Year 2022-23

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: ₹5.21 (vs ₹3.60 in 3Q 2022)

Poly Medicure Limited to Report Q3, 2023 Results on Jan 28, 2023

Price target increased to ₹1,021

Price target increased to ₹1,021

Second quarter 2023 earnings released: EPS: ₹4.53 (vs ₹3.99 in 2Q 2022)

Poly Medicure Limited to Report Q2, 2023 Results on Nov 04, 2022

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Investor sentiment improved over the past week

Poly Medicure Limited Appoints Ambrish Mithal as Independent Director

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Upcoming dividend of ₹2.50 per share